Risk factors for carbapenem resistance and outcomes when treating bloodstream infections in a paediatric intensive care unit

Acta Paediatr. 2019 Oct;108(10):1923-1924. doi: 10.1111/apa.14923. Epub 2019 Jul 30.

Authors

Violetta Magdalini Darda¹, Elias Iosifidis¹, Charalampos Antachopoulos¹, Elena Volakli², Anna Bettina Haidich³, Eleni Vagdatli⁴, Maria Sdougka², Emmanuel Roilides¹

Affiliations

¹ Infectious Disease Unit, 3rd Department of Pediatrics, Medical Faculty, Aristotle University School of Health Sciences, Hippokration General Hospital, Thessaloniki, Greece.
² Pediatric Intensive Care Unit, Hippokration General Hospital, Thessaloniki, Greece.
³ Department of Hygiene and Epidemiology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁴ Microbiology Department, Hippokration General Hospital, Thessaloniki, Greece.

PMID: 31265146
DOI: 10.1111/apa.14923

No abstract available

MeSH terms

Adolescent
Bacteremia / drug therapy*
Carbapenems / therapeutic use*
Child
Child, Preschool
Female
Humans
Infant
Intensive Care Units, Pediatric
Male
Retrospective Studies
beta-Lactam Resistance*

Substances

Carbapenems